Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Microsatellite Stable Rectal Carcinoma: early-phase trial registry

1 of 1 indexed Microsatellite Stable Rectal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Microsatellite Stable Rectal Carcinoma: 1 US clinical trial tracked, 1 recruiting.

Microsatellite Stable Rectal Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition microsatellite-stable-rectal-carcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Microsatellite Stable Re (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Microsatellite Stable Rectal Carcinoma

Microsatellite Stable Rectal Carcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Microsatellite Stable Rectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Microsatellite Stable Rectal Carcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Microsatellite Stable Rectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Botensilimab Drug
1 trials
Balstilimab Drug
1 trials

US sites by state

Facility locations filed on Microsatellite Stable Rectal Carcinoma trials. A trial with sites in several states counts in each.

New York 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Microsatellite Stable Rectal Carcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Microsatellite Stable Rectal Carcinoma condition card totals 1 registered trials; most-linked intervention Botensilimab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.